RG6468
/ Roche
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
July 30, 2025
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=250 | Recruiting | Sponsor: Genentech, Inc. | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2026 ➔ Dec 2027
Trial completion date • Trial primary completion date • Solid Tumor
November 03, 2023
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=250 | Recruiting | Sponsor: Genentech, Inc. | Not yet recruiting ➔ Recruiting
Combination therapy • Enrollment open • Metastases • Oncology • Solid Tumor
September 11, 2023
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=250 | Not yet recruiting | Sponsor: Genentech, Inc.
Combination therapy • Metastases • New P1 trial • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1